martedì, 27 luglio 2021
14 Luglio 2017

FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL

July 12, 2017 – The FDA has granted a full approval to blinatumomab as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen. The approval was based on … (leggi tutto)